Tipifarnib, a farnesyltransferase inhibitor (FTI) affecting the post-translational modification of HRAS to prevent membrane binding, demonstrated clinical activity in an open-label Phase-II study of patients with HRAS-mutated (HRASmt) head and neck cancer, with an objective response rate of 55% [11]. The gene discussed is HRAS; the disease is head and neck cancer.